

type of report	Current report
Number	78/2012
Company	PHARMENA

**Entering into an agreement on carrying out phase II clinical trials of anti-atherosclerosis medicinal product 1-MNA**

The Management Board of PHARMENA S.A. informs that on 20<sup>th</sup> November 2012, its subsidiary company Cortria Corp. (USA) received a signed agreement with Montreal Heart Institute on carrying out phase II clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA (working name of the product TRIA-662).

It is planned that phase II clinical trials ("Proof of Concept") will be randomised, multicentre, placebo controlled, on a total group of several dozen patients (two testing groups: placebo, 1-MNA). The study will monitor key parameters of lipid profile (among others TG level, HDL, LDL and TC), inflammation (CRP, IL6) and parameters related with the product's safety (among others glucose, ALT, ASP). The goal of the above research is to establish effective posology and confirm absence of adverse side effects in humans with increased doses. The intended duration of the research is 12 months since obtaining consent from the market's regulatory authority – Health Canada.

Montreal Heart Institute is a leading scientific research centre in Canada which specialises in cardiology. It is one of the most major institutes of this kind all over the globe. It is a world-renowned centre which introduced many innovative solutions both in Canada and worldwide. For more information please visit [www.icm-mhi.org](http://www.icm-mhi.org).

Entering into the agreement lies within the realisation of the Company's updated Strategy for 2012-2015 in the scope of research of innovative anti-atherosclerosis medicinal product (the Issuer informed about the strategy's assumptions in current report no. 16/2012 of 13<sup>th</sup> April 2012).

The information is made public due to the fact that the above agreement is crucial for the process of commercialisation of the 1-MNA anti-atherosclerosis medicinal product project, and potential revenue form it may have considerable influence on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (2.2).

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board